Bruton's tyrosine kinase inhibitor - Bristol-Myers Squibb

Drug Profile

Bruton's tyrosine kinase inhibitor - Bristol-Myers Squibb

Alternative Names: Btk inhibitor - BMS; BTK-Max

Latest Information Update: 11 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Amides; Purines; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors; Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Immunological disorders

Most Recent Events

  • 11 Apr 2018 Phase I development in Immunological disorders is ongoing (Bristol-Myers Squibb pipeline, April 2018)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Immunological-disorders in USA (PO)
  • 02 Mar 2011 Preclinical development in Immunological disorders is ongoing in US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top